ASH20: uniQure presents strong data for its gene therapy EtranaDez in haemophilia B patients, aims for BLA in 2021

shutterstock_394913866
The gene therapy achieved its primary endpoint of an increase in factor IX (FIX) activity levels at 26 weeks after treatment. Credit: Marietjie / Shutterstock.